Table 2. Comparison of clinicopathological variables between PSA responders vs. nonresponders.
| Variable | PSA responder (n=56) | PSA nonresponder (n=24) | p-value |
|---|---|---|---|
| Age (y) | 67.7±6.57 | 67.4±7.17 | 0.768 |
| Preoperative PSA (ng/mL) | 13.5±20.8 | 16.9±12.76 | 0.028 |
| Biopsy core (%) | 37.2±23.20 | 49.3±30.02 | 0.117 |
| Prostate volume (mL) | 38.1±16.51 | 37.9±16.98 | 0.949 |
| Nadir PSA | 0.044±0.02 | 0.074±0.07 | 0.030 |
| Radical prostatectomy | 0.503 | ||
| Retropubic | 13 | 8 | |
| Laparoscopic | 12 | 3 | |
| Robot-assisted laparoscopic | 31 | 13 | |
| Biopsy Gleason score | 0.035 | ||
| ≤6 | 34 | 8 | |
| 7 (3+4) | 13 | 5 | |
| 7 (4+3) | 1 | 2 | |
| ≥8 | 8 | 9 | |
| Pathological T stage | 0.216 | ||
| 2a | 17 | 5 | |
| 2b | 2 | 3 | |
| 2c | 29 | 11 | |
| 3a | 5 | 1 | |
| 3b | 3 | 4 | |
| Positive surgical margin | 0.495 | ||
| No | 49 | 19 | |
| Yes | 7 | 5 | |
| Pathological Gleason score | 0.346 | ||
| ≤6 | 24 | 7 | |
| 7 (3+4) | 17 | 6 | |
| 7 (4+3) | 5 | 5 | |
| ≥8 | 10 | 6 |
PSA, prostate-specific antigen.